Role of Hypothermia in Endovascular Stroke Thrombectomy
COOLING
Efficacy and Safety of Endovascular Thrombectomy With Versus Without Hypothermia in Acute Large Vessel Occlusion Stroke: a Randomized Controlled Trial
1 other identifier
interventional
200
0 countries
N/A
Brief Summary
Reducing or suspending the increase of the infarcted core, i.e., "freezing" the ischemic penumbra, may help improve the efficacy of mechanical thrombectomy. Hypothermia effectively reduces the metabolic level of brain tissue, may prolong the time window for recanalization therapy, and its multi-target therapeutic effect make it one of the most promising neuro-protection approach. In recent years, hypothermia has been increasingly used to treat acute ischemic stroke. However, its role in acute ischemic stroke is unclear. The objective of this trial is to investigate whether hypothermia combined with endovascular thrombectomy could add additional benefit without increasing the risk of adverse events such as pneumonia, intracerebral hemorrhage, and mortality.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Dec 2023
Longer than P75 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 22, 2023
CompletedFirst Posted
Study publicly available on registry
October 31, 2023
CompletedStudy Start
First participant enrolled
December 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 31, 2027
October 31, 2023
October 1, 2023
3.1 years
October 22, 2023
October 25, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Modified Rankin scale score (mRS)
Modified Rankin scale score (mRS): scores range from 0 to 6, with 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death
90 days post-randomization
Secondary Outcomes (15)
Excellent outcome
90 days post-randomization
Functional independence
90 days post-randomization
Moderate outcome
90 days post-randomization
Early neurological improvement
72 hours post-randomization
EQ-5D-5L scale score
90 days post-randomization
- +10 more secondary outcomes
Study Arms (2)
Hypothermia
EXPERIMENTALPatients in Hypothermia group received hypothermia combined with endovascular thrombectomy.
Control
ACTIVE COMPARATORPatients in Control group received endovascular thrombectomy alone.
Interventions
In this trial, intra-arterial select cooling infusion is used to reduce brain tissue temperature to 33-35°C.
Thrombectomy includes treatment with stent retrievers and/or thromboaspiration, balloon angioplasty, stenting, intra-arterial thrombolysis, or the various combinations of these approaches.
Eligibility Criteria
You may qualify if:
- Aged ≥ 18 years or more;
- acute ischemic stroke within 24 hours from onset to randomization;
- NIHSS ≥6 points before randomization;
- Internal carotid artery, or the middle cerebral artery M1 or M2 occlusion confirmed by CTA/MRA/DSA;
- Baseline ASPECTS score ≥ 3 and ≤8, or cerebral infarction core volume \< 100ml;
- The patient decides to undergo endovascular therapy;
- The patient or patient's representative signs a written informed consent form.
You may not qualify if:
- CT or MR evidence of hemorrhage;
- Currently pregnant or lactating (women patients);
- Allergy to radiographic contrast agents, or nitinol devices;
- Arterial tortuosity and/or other arterial disease that would prevent the device from reaching the target vessel;
- Multiple vessel occlusion (e.g., bilateral anterior circulation, or occlusion of both anterior and posterior circulation);
- Preexisting neurological or psychiatric disease that would confound the neurological functional evaluations;
- Previous bleeding disorders, severe heart, liver or kidney disease, or sepsis;
- Brain tumors with mass effect (except meningiomas) that are radiographically pleasant;
- Intracranial aneurysm, arteriovenous malformation;
- Any terminal illness with life expectancy less than 6 months;
- Participating in other clinical trials.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Xinqiao Hospital of Chongqinglead
- Xiangtan Central Hospitalcollaborator
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
October 22, 2023
First Posted
October 31, 2023
Study Start
December 1, 2023
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
March 31, 2027
Last Updated
October 31, 2023
Record last verified: 2023-10
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
- Time Frame
- 3 years after the trial results are revealed.
- Access Criteria
- after approval of a proposal from principal investigator
Study Protocol, Statistical Analysis Plan, Informed Consent Form, Clinical Study Report, and Analytic Code will be shared after approval of a proposal from principal investigator 3 years after the trial results are revealed.